

## HR 985

FAST Generics Act of 2019

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Feb 5, 2019

**Current Status:** Referred to the House Committee on Energy and Commerce.

**Latest Action:** Referred to the House Committee on Energy and Commerce. (Feb 5, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/985>

### Sponsor

**Name:** Rep. Welch, Peter [D-VT-At Large]

**Party:** Democratic • **State:** VT • **Chamber:** Senate

### Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cicilline, David N. [D-RI-1]	D · RI		Feb 5, 2019
Rep. McKinley, David B. [R-WV-1]	R · WV		Feb 5, 2019
Rep. Cartwright, Matt [D-PA-8]	D · PA		Mar 11, 2019
Rep. Slotkin, Elissa [D-MI-8]	D · MI		May 20, 2019

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Feb 5, 2019

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

*No related bills are listed.*

### Summary (as of Feb 5, 2019)

#### Fair Access for Safe and Timely Generics Act of 2019 or the FAST Generics Act of 2019

This bill generally prohibits the license holder of a drug or biological product approved by the Food and Drug Administration from restricting availability of the drug or product for testing by a product developer seeking to develop a drug, generic drug, or biosimilar.

## Actions Timeline

---

- **Feb 5, 2019:** Introduced in House
- **Feb 5, 2019:** Referred to the House Committee on Energy and Commerce.